Last reviewed · How we verify
Rapid Acting Intramuscular Olanzapine
Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.
Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist. Used for Treatment of schizophrenia, Treatment of bipolar disorder.
At a glance
| Generic name | Rapid Acting Intramuscular Olanzapine |
|---|---|
| Also known as | LY170053, olanzapine, RAIM |
| Sponsor | Eli Lilly and Company |
| Drug class | atypical antipsychotic |
| Target | D2 receptor, 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By blocking these receptors, olanzapine reduces the activity of dopamine and serotonin in the brain, which helps to alleviate symptoms of psychosis and mania. This is thought to be due to the drug's ability to modulate the activity of these neurotransmitters and their receptors.
Approved indications
- Treatment of schizophrenia
- Treatment of bipolar disorder
Common side effects
- Weight gain
- Dizziness
- Somnolence
- Dry mouth
- Headache
Key clinical trials
- A Study of Olanzapine in Patients With Schizophrenia (PHASE3)
- A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia (PHASE3)
- A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |